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Objectives
1. Compare & contrast the clinical manifestations and 
criteria for diagnosis of ADHD in adults & children.
2. Review treatment options for adults with ADHD.
3. Differentiate between abuse & misuse of medications.
4. Identify risk factors which may predispose adults to 
abuse & dependence to stimulant therapy for ADHD.
5. Discuss strategies for preventing misuse & abuse of 
stimulants.
ADHD Overview
 Most common neurodevelopmental disorder seen in children & 
adolescents
 Often persists into adulthood (~50%)
 Among these  90% are underdiagnosed & undertreated
 Associated with social, academic & economic limitations
 ↑ risk for SUD in adolescents & adults with ADHD
 Estimated worldwide prevalence:
Jain R, et al. Prim Care Companion CNS Disord. 2017;19(5)
Martinez-raga J, et al. Ther Adv Drug Saf. 2017;8(3):87-99.
Kollins SH. Curr Med Res Opin. 2008;24(5):1345-1357
Epidemiology. ADHD Institute. Accessed December 12, 2018.
Children & 
adolescents
5.3-7.1%
Adults age 18-
44 years 
1.2-7.3%
ADHD: Attention deficit hyperactivity disorder
SUD: Substance use disorder
Pathophysiology
 Exact pathogenesis unknown
 Complex, multifactorial 
disorder
 Disrupted DA & NE 
neurotransmission appears to 
play an important role
Martinez-raga J, et al. Ther Adv Drug Saf. 2017;8(3):87-99. imageDA: DopamineNE: Norepinephrine
Comorbidities
ADHD
Behavior 
problems
Anxiety & 
depression
Mood 
disorders
Learning 
disorders
SUD
Peer 
problems
Attention-Deficit/Hyperactivity Disorder. National Institute of Mental Health. Accessed December 10, 2018. SUD: Substance use disorder
Clinical Manifestations
Inattention Impulsiveness Hyperactivity
More prominent 
in adults
Jain R, et al. Prim Care Companion CNS Disord. 2017;19(5)
Kollins SH. Curr Med Res Opin. 2008;24(5):1345-1357 image
Differential Diagnoses
• Hearing impairment, thyroid disease, lead toxicity, hepatic 
disease, sleep apnea & drug interactions
Medical Conditions
• Anxiety, depression, mood disorders, obsessive-compulsive, 
SUD, bipolar disorder, antisocial personality & learning 
disorders
Psychiatric Conditions
• Anticonvulsants, antihistamines, caffeine, nicotine & steroids
Medications
Post RE, et al. Am Fam Physician. 2012 May 1;85(9):890-896. SUD: Substance use disorder
Diagnostic Approach
DSM-5 criteria 
& rating scales
Comprehensive 
clinical interview 
Assess for 
comorbidities
Assess risk for 
SUD
Physical exam
Post RE, et al. Am Fam Physician. 2012 May 1;85(9):890-896.
Attention-Deficit/Hyperactivity Disorder. National Institute of Mental Health. Accessed December 10, 2018.
DSM-5: Diagnostic and Statistical Manual of Mental Disorders. 5th edition
SUD: Substance use disorder
DSM-5
 Symptoms divided into 2 domains: 
 Inattention
 Hyperactivity/Impulsivity
 Diagnosis requires:
 ≥ 6 symptoms for children ages ≤ 16 or
 ≥ 5 symptoms for ages ≥ 17 
 Symptoms present for ≥ 6 months & inappropriate for 
developmental level
 Additional criteria:
 Several symptoms present before age 12 & in ≥ 2 settings
 Evidence that symptoms interfere with social, academic or 
occupational functioning
 Symptoms not caused by other psychiatric disorder
image
Attention-Deficit/Hyperactivity Disorder. National Institute of Mental Health. Accessed December 10, 2018.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. 2013
DSM-5: Inattention
Fail to pay close 
attention to 
details
Have difficulty 
sustaining 
attention
Easily distracted
Unable to follow 
instructions
Do not pay 
attention when 
someone is 
talking
Have difficulty 
organizing tasks 
or activities
Avoid/dislike 
tasks that require 
sustained mental 
effort
Lose things 
necessary for 
tasks or 
activities
Forgetful in daily 
activities
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. 2013
DSM-5: Hyperactivity/Impulsivity
Fidget/tap hands 
or feet, or 
squirm in seat
Leave seat 
inappropriately
Run about or 
climb when not 
appropriate
“On the go” or 
act as if “driven 
by a motor”
Speak 
excessively
Unable to play 
quietly
Blurt out 
answers
Have trouble 
waiting his/her 
turn
Interrupt or 
intrude on 
others
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. 2013
Timeline: Functional Impairment
Jain R, et al. Prim Care Companion CNS Disord. 2017;19(5)
Overall Impact: ADHD
 Poor academic performance
 Problems at work
 ↑ rates of unemployment
 Difficult or failed relationships
 Dangerous driving & motor vehicle accidents
 Delinquent behavior
 Impulsive sexuality
 Self-esteem issues
 ↑ rates of SUD
Lakhan SE, Kirchgessner A. Brain Behav. 2012;2(5):661-77.
Attention-Deficit/Hyperactivity Disorder. National Institute of Mental Health. Accessed December 10, 2018.
Daily Challenges: Adult ADHD
Jain R, et al. Prim Care Companion CNS Disord. 2017;19(5)
Consequences of Untreated ADHD
 Major depression & anxiety
 Bipolar disorder
 SUD
 Conduct disorder
 Oppositional-defiant disorder
 Antisocial personality
 Suicide
Lakhan SE, Kirchgessner A. Brain Behav. 2012;2(5):661-77.
Attention-Deficit/Hyperactivity Disorder. National Institute of Mental Health. Accessed December 10, 2018.
Early treatment may ↓ negative outcomes
SUD: Substance use disorder
Treatment Options for 
Adults with ADHD
Treatment Overview
Assessment & diagnosis
Identify patient & family needs
Establish treatment goals
Initiate treatment
Treatment re-evaluation & monitoring 
Non-pharmacologic Treatment
 Helpful as adjunct to medication
 Behavioral therapies may be better 
options for patients with comorbid 
ADHD & SUD 
 May ↓ risk for misuse, abuse & diversion
 Future studies assessing multimodal 
treatment strategies are needed
image
Chang Z, et al. J Child Psychol Psychiatry. 2014;55(8):878-85.
Prescription Stimulants. National Institute on Drug Abuse. Accessed December 30, 2018.
Wilens TE, et al. Neuropsychiatry (London). 2012;2(4):301-312.
CBT: Cognitive behavioral therapy
SUD: Substance use disorder
 Options:
 Behavioral therapies (CBT)
 Psychoeducation
 Lifestyle & diet
Pharmacotherapy
Jain R, et al. Prim Care Companion CNS Disord. 2017;19(5)
Treatment 
Options
Stimulants  
(1st line)
Methylphenidate 
(MPH)
Amphetamine 
(AMP)
Non-
stimulants 
Atomoxetine 
(ATX)
Stimulants: MOA
imageMOA: Mechanism of action
Stimulants: Overview
 Safe & effective when used as prescribed
 Appropriate use = lower risk for misuse of alcohol & other illicit drugs
 Rapid onset of action (≤ 1 hr)
 Classified as schedule II by the FDA
 High potential for abuse, which may lead to physiological and/or 
psychological dependence
 Black Boxed Warning:
 Abuse & dependence (all stimulants)
Weyandt LL, et al. Psychol Res Behav Manag. 2014;7:223-49. FDA: Food and Drug Administration image
Stimulants:
Amphetamines
Cortese S, et al. Lancet Psychiatry 2018; 5:727.
Lexi-Drugs. Lexicomp. Wolters Kluwer Clinical Drug Information, Inc. Hudson, OH. Accessed on December 20, 2018.
Recent meta-analysis concluded AMP moderately more efficacious than 
MPH in reducing core ADHD symptoms
image
ODT: Orally disintegrating tablet
AMP: Amphetamine
MPH: Methylphenidate image
image
Stimulants: 
Methylphenidate
imageLexi-Drugs. Lexicomp. Wolters Kluwer Clinical Drug Information, Inc. Hudson, OH. Accessed on December 20, 2018.
image
image
ODT: Orally disintegrating tablet
Stimulants: 
Adverse Effects & Monitoring
Common Adverse Effects: (dose-dependent)
 ↓ appetite, weight loss, headache, insomnia, abdominal pain, 
nausea/vomiting, dizziness, nervousness, emotional lability
Monitoring Parameters:
 Prior to initiation: Assess history and/or risk of abuse, cardiac 
history, consider obtaining ECG
 After initiation: Signs of misuse and/or abuse, BP, HR, chest 
pain, unexplained syncope, behavioral changes
Weyandt LL, et al. Psychol Res Behav Manag. 2014;7:223-49.
Lexi-Drugs. Lexicomp. Wolters Kluwer Clinical Drug Information, Inc. Hudson, OH. Accessed on December 20, 2018.
Stimulants: Benefits & Downfalls
Benefits (when used appropriately)
 Improve sustained, focused attention (vigilance)
 May improve executive function
 May improve long-term retention of information
 Facilitate consolidation of information
Downfalls
 May worsen selective attention & distractibility
 Do not improve (may impair) short-term acquisition of 
information and/or cognitive flexibility
 Not shown to improve learning & application of knowledge
Advokat C. Neurosci Biobehav Rev. 2010;34(8):1256-66.
Munro BA, et al. Addict Behav. 2017;65:250-257.
Weyandt LL, et al. Psychol Res Behav Manag. 2014;7:223-49.
Non-Stimulants: Overview
 Option for individuals who fail stimulant therapy or if 
stimulants contraindicated
 Recommended for patients with comorbid ADHD & SUD
 Less potential for abuse than stimulants
 Variable onset of action  2-4 weeks
Weyandt LL, et al. Psychol Res Behav Manag. 2014;7:223-49.
Lexi-Drugs. Lexicomp. Wolters Kluwer Clinical Drug Information, Inc. Hudson, OH. Accessed on December 20, 2018. image
Non-Stimulants: 
Atomoxetine (Strattera®)
 Only FDA-approved non-stimulant for treating adult ADHD
 MOA: Selective NE Reuptake Inhibitor (SNRI)
 Little to no abuse potential
 Duration of action: 24 hrs 
 Onset of action: 1-2 weeks
image
Jain R, et al. Prim Care Companion CNS Disord. 2017;19(5)
Lexi-Drugs. Lexicomp. Wolters Kluwer Clinical Drug Information, Inc. Hudson, OH. Accessed on December 20, 2018.
Non-Stimulants:
Bupropion (Wellbutrin®)
 Off-label use 
 MOA: relatively weak inhibitor of NE & DA reuptake
 Option for adults with comorbid ADHD & depression
 Onset of action: 1-2 weeks
 Duration of action: 12 hrs (SR) to  24 hrs (XL)
image
Currently no direct comparisons of efficacy 
between bupropion & stimulants in adult 
ADHD
Lexi-Drugs. Lexicomp. Wolters Kluwer Clinical Drug Information, Inc. Hudson, OH. Accessed on December 20, 2018. NE: NorepinephrineDA: Dopamine
Non-Stimulants:
Modafinil (Provigil®)
 Off-label use
 MOA: Blocks DA transporters, significantly ↑ DA in the brain 
 ↓ affinity for DA receptors compared to AMP
 Classified as Schedule IV by FDA
 Lower potential for abuse than schedule III drugs; abuse may lead to 
limited physical or psychological dependence relative to schedule III drugs
Bagot KS, et al. Addiction. 2014;109(4):547-557
Lexi-Drugs. Lexicomp. Wolters Kluwer Clinical Drug Information, Inc. Hudson, OH. Accessed on December 20, 2018. image
 Appears to improve reaction time, 
logical reasoning & problem-solving
image
DA: Dopamine
Non-Stimulants: Other
Alpha-2 Agonists
 Guanfacine (Intuniv®) & Clonidine (Kapvay®)
 FDA approved for treatment of ADHD in children ages 6-17
 Efficacy, safety & tolerability in adult ADHD not well known
Antidepressants
 Nortriptyline (Pamelor®, Aventyl®)
 Desipramine (Norpramin®)
 Imipramine (Tofranil®)
 Venlafaxine (Effexor® & Effexor XR®)
 Shown to be less effective & more poorly tolerated than 
stimulants
Lexi-Drugs. Lexicomp. Wolters Kluwer Clinical Drug Information, Inc. Hudson, OH. Accessed on December 20, 2018.
Misuse & Abuse of 
Prescription Stimulants
Medication Misuse
Misuse definition:
 Using a medication with a therapeutic intent but taking it 
inappropriately
 Use does not involve seeking psychotropic or euphoric effects
 Examples:
 Taking Rx medication without a Rx and/or for reasons other than 
prescribed, taking higher doses than prescribed, accepting or stealing 
Rx medication from a friend or relative
 Misuse ≈ Non-medical use
 Can lead to abuse & dependence
Smith SM, et al. Pain. 2013;154(11):2287-96.
Wilens TE, et al. J Am Acad Child Adolesc Psychiatry. 2008;47(1):21-31
Stimulant Misuse: Overview
 2nd only to marijuana as most common form of illicit drug use
 Prevalence  13-23% (17% on average)
 Greatest risk among individuals 18 -25 years of age
 Per SAMHSA  ~ 15.4 million adults reported past-year use of Rx 
stimulants in 2015
 ~4.8 million (30.9%) misused Rx stimulants at least once in the past year
 Individuals both with & without ADHD misuse Rx stimulants
 Common sources  friends & relatives
Smith SM, et al. Pain. 2013;154(11):2287-96.
Lakhan SE, et al. Brain Behav. 2012;2(5):661-77.
Wilens T, et al. J Am Acad Child and Adolesc Psychiatry. 2006;45(2):149–157. 
Kroutil LA, et al. Drug Alcohol Depend. 2006;84(2):135-43
Weyandt LL, et al. Exp Clin Psychopharmacol. 2016;24(5):400-414.
Lipari RN, et al. Why do adults misuse prescription drugs? National Survey on Drug Use and Health. Accessed December 21, 2018.
SAMSHA: Substance Abuse and 
Mental Health Services Administration
Misuse Comparison
imageLipari RN, et al. Why do adults misuse prescription drugs? National Survey on Drug Use and Health. Accessed December 21, 2018.
Stimulant Misuse: Motives
imageLipari RN, et al. Why do adults misuse prescription drugs? National Survey on Drug Use and Health. Accessed December 21, 2018.
Stimulant Misuse: 
College Students
 Exact prevalence of ADHD among college students unknown
 Rates of misuse  8-34%
 Estimated lifetime prevalence  5.3-55%
 ↑ rates of misuse among college students diagnosed with ADHD 
(43%) or those with Rx for stimulants (45.2%)
 Highest rates among fraternity members (55%)
 Risk factors: 
 Male, Caucasian, member of fraternity/sorority, low GPA, illicit drug use 
 Found to be negatively associated with academic performance 
(i.e. poorer study skills, skipping class, procrastination, lower GPA)
Lakhan SE, et al. Brain Behav. 2012;2(5):661-77.
Austic EA, Meier EA. Drug Alcohol Depend. 2015;152:224-9.
Benson K, et al. Clin Child Fam Psychol Rev. 2015;18(1):50-76.
Weyandt LL, et al. Psychol Res Behav Manag. 2014;7:223-49.
Arria AM, et al. J Drug Issues. 2008;38(4):1045–1060 
Stimulant Misuse:
Graduate Health Care Students
 Lifetime prevalence of misuse:
 Pharmacy students  7%
 Graduate health care students  11%
 Dental & dental hygiene students  12.4%
 Medical students are a high risk population
 Lifetime prevalence  20%
 Prevalence of use during medical school  15%
 Common motives  cognitive enhancement & staying awake
Webb JR, et al. Ann Clinical Psychiatry. 2013;25(1):27-32
Lakhan SE, et al. Brain Behav. 2012;2(5):661-77.
Weyandt LL, et al. Psychol Res Behav Manag. 2014;7:223-49.
High prevalence among medical students may influence future prescribing 
patterns & physician attitudes towards patients seeking Rx stimulants
Stimulant Misuse:
Adults Outside University Setting
 Few studies have addressed the prevalence of Rx stimulant 
misuse among adults outside the university setting
 Reported lifetime prevalence  7.1-29%
 ↑ rates reported among adults with Rx for stimulants
 2006 - 2011:
 Misuse of Rx stimulants by adults in general population ↑ by ~67% 
 ER visits ↑ by ~156%
 Rx stimulants involved in ER visit:
• MAS  21%
• MPH  18.2%
Darredeau C, et al. Hum Psychopharmacol. 2007;22(8): 529–536.
Weyandt LL, et al. Psychol Res Behav Manag. 2014;7:223-49.
Chen LY, et al. J Clin Psychiatry. 2016;77(3):e297-304.
ER: Emergency room
MAS: Mixed amphetamine salts
MPH: Methylphenidate
Diversion of Stimulants
Diversion definition: 
 The act of buying, receiving for free, trading or stealing a 
medication from an individual for whom it was prescribed. 
 May begin in childhood, adolescence or young adulthood
 Reported lifetime diversion rates  16-29% of students with Rx 
for stimulants
 One study reported diversion in 23.3% of middle/high school 
students & 54% of college students
Rabiner DL. Curr Psychiatry Rep. 2013;15(7):375
Lakhan SE, et al. Brain Behav. 2012;2(5):661-77.
Wilens TE, et al. J Am Acad Child Adolesc Psychiatry. 2008;47(1):21-31.
McCabe SE, et al. Addiction 2005;100:96–106. image
Medication Abuse
Abuse definition:
 Taking a medication for non-therapeutic purposes to obtain 
psychotropic or euphoric effects; often leads to addiction & 
dependence
 Addiction: compulsive substance use despite personal harm or negative 
consequences
 Dependence: associated with cravings, withdrawal symptoms and/or 
development of tolerance
 Examples:
 Using medication to ‘get high’, exceeding recommended dose, continuing to 
take a medication after no longer needed (medically), compulsive use, not 
able to carry out normal daily activities
Smith SM, et al. Pain. 2013;154(11):2287-96.
Wilens TE, et al. J Am Acad Child Adolesc Psychiatry. 2008;47(1):21-31
Chang Z, et al. J Child Psychol Psychiatry. 2014;55(8):878-85.
Stimulant Abuse
 Theory behind abuse:
 Stimulants ↑ DA concentrations in 
the brain
• DA is involved in reinforcement 
of rewarding behaviors
• Presumed to mediate abuse 
potential
image
Martinez-raga J, et al. Ther Adv Drug Saf. 2017;8(3):87-99.
Chang Z, et al. J Child Psychol Psychiatry. 2014;55(8):878-85.
Kroutil LA, et al. Drug Alcohol Depend. 2006;84(2):135-43.
 Approximately 80% of Rx stimulant abusers  ages 12-25 years
 Influencing factors:
 Dose, PK properties, route of administration, individual personality traits, 
context of use, concomitant psychiatric medications, co-morbid 
psychiatric disorders or concurrent illicit drug use
DA: Dopamine
PK: Pharmacokinetic
Risk Factors for SUD in ADHD
Kollins SH. Curr Med Res Opin. 2008;24(5):1345-1357
White BP, et al. J Am Coll Health. 2006;54(5):261-268
Starting Rx 
stimulants later 
in course of 
ADHD
Severe ADHD
Antisocial 
personality 
disorders
Bipolar 
disorder
Eating 
disorders
Dropping out 
of school
SUD: Substance use disorder
Does Stimulant Use Lead to SUD?
 Research shows that people of any age receiving Rx 
stimulants for ADHD are not at ↑ risk for SUD compared to 
the general population 
 Rx stimulant use (specifically MPH) during childhood for 
ADHD does not appear to affect the risk of SUD in adulthood
Biederman J, et al. Am J Psychiatry. 2008; 165(5):597-603
Mannuzza S, et al. Am J Psychiatry. 2008;165(5):604-609
Kollins SH. Curr Med Res Opin. 2008;24(5):1345-1357
Chang Z, et al. J Child Psychol Psychiatry. 2014;55(8):878-85. image
One review showed 
↓ risk of SUD by 
~27%
SUD: Substance use disorder
MPH: Methylphenidate
Consequences of Stimulant 
Misuse & Abuse
Adverse events:
 Heart failure
 Myocardial infarction
 Stroke
 Arrhythmias
 Cardiomyopathy
Lakhan SE, et al. Brain Behav. 2012;2(5):661-77.
Weyandt LL, et al. Psychol Res Behav Manag. 2014;7:223-49.
Risk even higher when combined with other drugs or alcohol
 Hypertension
 Seizures
 Paranoia
 Psychosis
 Sudden death
Stimulant Overdose
 Signs & symptoms :
 Hyperthermia, agitation, tachycardia, hyperhidrosis, tachypnea, ↑ BP,
palpitations, chest pain, mydriasis, restlessness, convulsions, seizures, 
psychosis, nausea, vomiting, abdominal pain
 Complications:
 Rhabdomyolysis, liver/kidney damage, cognitive deficit, death (rare)
 Inpatient Management:
 Mainly supportive care measures 
 Activated charcoal or gastric lavage
 Benzodiazepines  for sedation or persistent seizures
 Antipsychotics  for agitation & psychosis
 Temperature control  within 15-20 minutes
Chen LY, et al. J Clin Psychiatry. 2016;77(3):e297-304.
Preventing Misuse & Abuse: 
Role of Prescribers
 Prescribing physicians (major source for misuse & abuse)
 Estimated 20% of individuals misusing Rx stimulants obtain them by 
fraudulently misrepresenting symptoms of ADHD to physicians
 Proper diagnosis & treatment of ADHD
 Consider comorbidities & baseline risk for SUD
 Prescribe medications with ↓ potential for misuse & abuse
 Pro-stimulant, LA Rx stimulant formulations, non-stimulants
 Avoid IR & SA formulations in patients at ↑ risk for SUD 
Weyandt LL, et al. Psychol Res Behav Manag. 2014;7:223-49.
Novak SP, et al. Subst Abuse Treat Prev Policy. 2007;2:32
Modesto-lowe V, et al. Cleve Clin J Med. 2015;82(8):506-12. SUD: Substance use disorder
Preventing Misuse & Abuse: 
Role of Prescribers (cont.)
 Educate patients on addictive 
nature of Rx stimulants 
 Re-evaluate patients periodically 
for need to continue Rx stimulant 
treatment
 Consider drug-free periods
 Regularly monitor adult use of Rx 
stimulants for ADHD
 Check PDMP
Weyandt LL, et al. Psychol Res Behav Manag. 2014;7:223-49.
Novak SP, et al. Subst Abuse Treat Prev Policy. 2007;2:32
Modesto-lowe V, et al. Cleve Clin J Med. 2015;82(8):506-12. PDMP: Prescription Drug Monitoring Program
PDMPs
 House Bill 21 
 Requires consultation of PDMP 
prior to prescribing or 
dispensing a controlled 
substance to a patient ≥ 16 
years of age
 Dispensing must be reported 
to database no later than close 
of next business day
image
 State-run programs designed to encourage safer prescribing & 
prevent abuse of controlled substances
 Electronic monitoring of the prescribing and dispensing of 
controlled substances
 E-FORCSE = PDMP in Florida
E-FORCSE, Florida’s Prescription Drug Monitoring Program. Accessed December 17, 2018
Scott J. Florida’s New Law on Controlled Substance Prescribing. Accessed December 17, 2018
PDMP: Prescription Drug Monitoring Program
E-FORCSE: Electronic-Florida Online Reporting of 
Controlled Substances Evaluation Program
Preventing Misuse & Abuse: 
Role of Pharmacists
 Counsel patients on:
 Using Rx stimulants only as prescribed
 Health & legal risks associated with misuse & diversion of Rx 
stimulants (provide medication guides)
 Importance of safe storage of medication
 Dangers of co-ingestion of Rx stimulants with alcohol and/or other 
illicit substances
 Frequent monitoring to ensure appropriate use
 Check PDMP
 Watch for ADHD medication shopping (i.e. overlapping 
prescriptions by ≥ 2 prescribers & filled at ≥ 3 pharmacies)
Cepeda MS, et al. Drugs R D. 2014;14(3):205-11. PDMP: Prescription Drug Monitoring Program
Summary
 Failure to diagnose and treat ADHD in adults is linked to 
negative outcomes & ↑ risk for SUD
 Pro-stimulant (LDX) & LA Rx stimulant formulations less prone 
to misuse, abuse & diversion
 Non-stimulants are preferred options for ADHD patients at ↑ 
risk for SUD 
 Future studies needed to assess prevalence & factors 
associated with adult Rx stimulant misuse outside the 
university setting
 Prevention strategies are key!
SUD: Substance use disorder
LDX: Lisdexamfetamine
True or False?
1. Clinical manifestations of ADHD are the same in 
both adults & children. 
2. Behavioral therapies, such as CBT, may be effective 
in preventing misuse & abuse of Rx stimulant 
medications in patients at ↑ risk for SUD
3. Rx stimulant medications ↑ the activity of certain 
neurotransmitters, such as DA & NE.
F
T
T
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